Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis in High Risk Patients: Searching for the Optimal Dose. A Prospective Randomized Trial
Study on the Effectiveness of an Investigational Medication to Reduce Pancreatitis Risk During Endoscopic Retrograde Cholangiopancreatography (ERCP)
Brief description of study.
The purpose of this study is to determine if a higher dose of a suppository of a drug called indomethacin at the time of ERCP can further decrease the risk of pancreatitis related to the procedure.
Detailed description of study
The purpose of this study is to determine if a higher dose of a suppository of a drug called indomethacin at the time of ERCP can further decrease the risk of pancreatitis related to the procedure.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Pancreatitis
-
Age: 18 years - 100 years
-
Gender: All
This study investigates the use of an investigational medication in the form of a suppository to see if a higher dose can reduce the risk of pancreatitis, which is inflammation of the pancreas, after a procedure called ERCP. ERCP stands for Endoscopic Retrograde Cholangiopancreatography, a procedure used to examine the pancreatic and bile ducts.
Participants in this study will receive either a higher dose of the investigational medication or a placebo, which is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will assess the effectiveness of the higher dose in preventing pancreatitis after the ERCP procedure.
- Who can participate: The eligibility criteria for this study have not been specified.
- Study details: Participants will receive either a higher dose of the investigational medication or a placebo.
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or